| Literature DB >> 26070514 |
Matteo Santoni1, Marina Scarpelli2, Roberta Mazzucchelli2, Antonio Lopez-Beltran3, Liang Cheng4, Jonathan I Epstein5, Stefano Cascinu1, Alberto Briganti6, James W Catto7, Francesco Montorsi8, Rodolfo Montironi9.
Abstract
Data on TMPRSS2-ERG and AR-V7 may pave the way for personalised therapy for prostate cancer (PCa) patients. Comprehensive molecular profiling can help identify multiple PCa subtypes and driving alterations. Translating these findings into clinical practice is still challenging.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26070514 DOI: 10.1016/j.eururo.2015.05.041
Source DB: PubMed Journal: Eur Urol ISSN: 0302-2838 Impact factor: 20.096